Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 26 February 1982:
Vol. 215. no. 4536, pp. 1115 - 1116
DOI: 10.1126/science.6278587
Prev | Table of Contents | Next

Articles

Science, Vol 215, Issue 4536, 1115-1116
Copyright © 1982 by American Association for the Advancement of Science

articles

Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist

DG Johnson, CU Goebel, VJ Hruby, MD Bregman, and D Trivedi

The glucagon analog [l-N alpha-trinitrophenylhistidine, 12-homoarginine]-glucagon (THG) was examined for its ability to lower blood glucose concentrations in rats made diabetic with streptozotocin. In vitro, THG is a potent antagonist of glucagon activation of the hepatic adenylate cyclase assay system. Intravenous bolus injections of THG caused rapid decreases (20 to 35 percent) of short duration in blood glucose. Continuous infusion of low concentrations of the inhibitor led to larger sustained decreases in blood glucose (30 to 65 percent). These studies demonstrate that a glucagon receptor antagonist can substantially reduce blood glucose levels in diabetic animals without addition of exogenous insulin.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
S. Ali and D. J. Drucker (2009)
Am J Physiol Endocrinol Metab 296, E415-E421
   Abstract »    Full Text »    PDF »
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications.
B. E. Dunning and J. E. Gerich (2007)
Endocr. Rev. 28, 253-283
   Abstract »    Full Text »    PDF »
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential.
E. M Sinclair and D. J. Drucker (2005)
Physiology 20, 357-365
   Abstract »    Full Text »    PDF »
Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?.
B. Raju and P. E. Cryer (2005)
Am J Physiol Endocrinol Metab 289, E181-E186
   Abstract »    Full Text »    PDF »
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects.
S. A. Qureshi, M. Rios Candelore, D. Xie, X. Yang, L. M. Tota, V. D.-H. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al. (2004)
Diabetes 53, 3267-3273
   Abstract »    Full Text »    PDF »
Glucagon and regulation of glucose metabolism.
G. Jiang and B. B. Zhang (2003)
Am J Physiol Endocrinol Metab 284, E671-E678
   Abstract »    Full Text »    PDF »
Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor.
M. A. Cascieri, G. E. Koch, E. Ber, S. J. Sadowski, D. Louizides, S. E. de Laszlo, C. Hacker, W. K. Hagmann, M. MacCoss, G. G. Chicchi, et al. (1999)
J. Biol. Chem. 274, 8694-8697
   Abstract »    Full Text »    PDF »
Positively Charged Residues at Positions 12, 17, and 18 of Glucagon Ensure Maximum Biological Potency.
C. G. Unson, C.-R. Wu, C. P. Cheung, and R. B. Merrifield (1998)
J. Biol. Chem. 273, 10308-10312
   Abstract »    Full Text »    PDF »
A parathyroid hormone inhibitor in vivo: design and biological evaluation of a hormone analog.
N Horiuchi, M. Holick, J. Potts Jr, and M Rosenblatt (1983)
Science 220, 1053-1055
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)